The main market opportunities in the RSV prophylaxis field lie in the development of new monoclonal antibodies and vaccines, with substantial growth expected due to late-stage pipeline products. This ...
As cold weather sets in, viruses such as influenza, RSV, and COVID-19 are resurfacing. Quickly identifying symptomatic ...
BRITS are being urged to look out for symptoms of RSV after an increase in cases of the highly contagious disease. The virus ...
People aged 75 to 79, as well as people who turned 80 after 1 September 2024, are eligible for a vaccine to protect against respiratory syncytial virus (RSV). RSV affects the airways and lungs and can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback